Vecoy Nanomedicines

Company Overview

Snapshot

Founded in October 2010 by Erez Livneh, Vecoy Nanomedicines operates with 1–10 employees. The company has raised $2 million across one funding round. In November 2013, Vecoy Nanomedicines secured a grant, marking a key milestone in its early development.

Business overview

Vecoy Nanomedicines develops novel nano-scale virus traps designed to capture and destroy viruses. Its patent-pending technology mimics human host cells to act as virus decoys, targeting viruses before cellular infection occurs. This approach aims to address challenges in existing antiviral treatments, such as virus resistance and toxicity. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharmaceuticals and Drug Delivery, and serves the United States market.

Strategic signal

In June 2016, Vecoy Nanomedicines' patent for 'PATHOGEN AND SUBSTANCE TRAPS' was published. This development signaled a significant validation of the company's core technology and its potential to introduce a new paradigm in antiviral therapy, moving beyond traditional methods that target infected cells to a preventative approach that directly neutralizes viruses.

Company Intelligence Q&A

What is Vecoy Nanomedicines' core technology?

Vecoy Nanomedicines develops nano-scale virus traps that mimic human host cells to capture and destroy viruses, targeting them before they can infect cells. This technology is designed to overcome issues of virus resistance and toxicity associated with current antiviral treatments.

When was Vecoy Nanomedicines founded?

Vecoy Nanomedicines was founded in October 2010 by Erez Livneh.

What was a significant intellectual property milestone for Vecoy Nanomedicines?

In June 2016, Vecoy Nanomedicines had its patent for 'PATHOGEN AND SUBSTANCE TRAPS' published, highlighting its innovative approach to antiviral therapy.

What is the company's operational status?

Vecoy Nanomedicines is currently non-active, having ceased operations in October 2018.

What was a notable early recognition for Vecoy Nanomedicines?

In December 2013, Vecoy Nanomedicines received an 'outer-space research prize' for its virus-killer technology, as reported by israel21c.org.